Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Integrin ligand" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The integrin family of proteins consists of alpha and beta subtypes, which form transmembrane heterodimers. Integrins function as adhesion receptors for extracellular ligands and transduce biochemical signals into the cell, through downstream effector proteins.
Alpha-4 beta-1 integrin ligands for imaging and therapy
ActiveUS20060019900A1High binding affinityStrong specificityMaterial nanotechnologyAntipyreticAutoimmune conditionAutoimmune disease
The present invention provides α4β1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
Owner:RGT UNIV OF CALIFORNIA
Long circulation liposome with modified integrin and carried anticancer medicine for injection
InactiveCN1846691AImprove therapeutic indexSmall molecular weightMacromolecular non-active ingredientsAntineoplastic agentsGlycineAnticarcinogen
The present invention relates to integrin ligand modified long circulation liposome carrying anticarcinogen for injection, and is especially one kind of injected anticarcinogen carrying targeting liposome administration system. The efficient administration system is obtained through modifying the surface of liposome simultaneously with both polyethylene glycol and integrin containing arginine-glycine-asparagic acid sequence or RGD analogue.
Owner:PEKING UNIV
Alpha-4 beta-1 integrin ligands for imaging and therapy
ActiveUS7576175B2High affinityStrong specificityMaterial nanotechnologyAntipyreticAutoimmune conditionAutoimmune disease
The present invention provides α4β1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
Owner:RGT UNIV OF CALIFORNIA
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
InactiveUS7211252B2Halting progressive bone destructionImprove the quality of lifeImmunoglobulin superfamilyPeptide/protein ingredientsIntegrin antagonistIntegrin ligand
Antagonists of alpha 4 integrin / alpha 4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their alpha 4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Integrin ligand cyclic peptide analogues and cyclization method
InactiveCN101492494AImprove biological activityThe cyclization method is simplePeptidesTrifluoromethanesulfonic anhydrideCyclic peptide
The invention relates to a cyclopeptide analog and a cyclization method thereof, which aims at providing an integrin ligand cyclopeptide analog and a cyclization method thereof. The cyclization method comprises the following steps: Azido-glycine is firstly generated by glycin with the effects of trifluoromethanesulfonic anhydride and Sodium azide; Fmoc-Asp-Propargyl is then generated by condensation with propargylamine in solution; after side-chain carboxyl of propargyl acyl aspartic acid is then hung on 2-CTC resin, linear tetrapeptide analogs are condensed in turn, and the linear tetrapeptide analogs are then cut down from the resin; and the cyclopeptide analog is synthesized in the condition of liquid phase (DCM is used as a solvent and CuBr / DBU is used as catalyst) after 4 to 6 hours of reaction at room temperature. The cyclopeptide analog and cyclization method has the following advantages: (1) the integrin ligand cyclopeptide analog in the invention is introduced with heterocyclic rings (triazole rings), thereby being capable of increasing biological activity; and (2) the cyclization method in the invention is more simple, convenient and high-efficient, and the condition is moderate.
Owner:ZHEJIANG UNIV
Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof
ActiveUS20100311948A1Good curative effectEliminate side effectsPeptide/protein ingredientsTumor necrosis factorSide effectPurification methods
Provided is a fusion protein comprising a tumor necrosis factor related apoptosis inducing ligand (TRAIL), integrin ligands of αVβ3 and αVβ5 and a linking peptide. Also provided are the expression method and simple separation and purification process for the production of the fusion protein which is soluble and has high content of the polymer, and use of the fusion protein for the manufacturing of a medicament for the treatment of tumor. The fusion protein has good tumor tissue targeting property, significantly enhanced anti-tumor effect, which can also reduce the dose of the needed protein for the target treatment effect, improve the bioavailability, reduce the treatment cost, decrease and overcome the potential toxic and side effects of the tumor necrosis factor-related apoptosis inducing ligand.
Owner:NANJING UNIV
Integrin blocking agent polypeptide and applications of the same in preparation of drugs for treatment of neovascular eye diseases
ActiveCN104327169ASuppress generationInhibition formationSenses disorderPeptide/protein ingredientsIntegrin ligandArg-Gly-Asp
The present invention discloses an integrin blocking agent polypeptide and applications of the same in preparation of drugs for treatment of neovascular eye diseases, and belongs to the field of medicine. The integrin blocking agent polypeptide comprises a polypeptide I Arg-Gly-Asp-Gly-Gly-Gly-Gly-Phe- Gln-Pro-Val-Leu-His-Leu-Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala and a polypeptide II Phe-Gln-Pro-Val-Leu-His-Leu-Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Al a-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp, wherein the polypeptide I is modified with the integrin ligand sequence (Arg-Gly-Asp-Gly-Gly-Gly-Gly). The integrin blocking agent polypeptide can be used for treatments of iridal neovascular eye diseases, choroidal neovascular eye diseases, retinal neovascular eye diseases or corneal neovascular eye diseases and other neovascular eye diseases.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD
Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
InactiveUS20050002904A1Easy adhesionEasy to spreadBiocidePeptide/protein ingredientsCell–cell interactionIntegrin ligand
Vascular endothelial growth factor and type I collagen inducible protein (VCIP), also known as phosphatidic acid phosphatase 2b (PAP2b), was identified in a functional assay of angiogenesis. Previously, VCIP was not known to function as an integrin ligand. The present invention discloses VCIP-derived peptides and proteins act as integrin ligands. Since VCIP-derived peptides or proteins are capable of inhibiting specific cell-cell interactions, such inhibitors of cell-cell interactions would be useful for developing novel therapeutic approaches to treat diseases where these interactions have clear pathological consequences. For example, VCIP / PAP2b can be a novel target for anti-angiogenic, anti-cancer and anti-metastatic therapy.
Owner:TEXAS A&M UNIVERSITY
Heterocyclic Ligands for Integrin Imaging and Therapy
ActiveUS20100310455A1High affinityStrong specificityAntipyreticAnalgesicsImmunologic disordersAutoimmune disease
The present invention provides α4β1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
Owner:RGT UNIV OF CALIFORNIA
Application of blood vessel inhibiting polypeptides with integrin affinity and bonding capability and MMPs (matrix metalloproteinases) inhibiting capability
ActiveCN104840941AII works wellInhibition formationSenses disorderPeptide/protein ingredientsDiseaseArginine
The invention discloses an application of a blocker with integrin affinity and bonding capability and MMPs (matrix metalloproteinases) inhibiting capability, and belongs to the field of medicines. The application comprises a polypeptide I (Arg-Gly-Asp-Gly-Gly-Gly-Gly-Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu) and a polypeptide II (Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu-Gly-Gly-Gly-Gly-Arg-Gly-Asp), wherein the polypeptide I is modified with an integrin ligand sequence (Arg-Gly-Asp-Gly-Gly-Gly-Gly); two types of blood vessel inhibiting polypeptides with integrin affinity and bonding capability are formed. The application has the advantages that because of the targeting property of an RGD (arginine-glycin-aspartate) sequence, the polypeptides can be targeted to the new blood vessel endothelium of the RA (rheumatoid arthritis) pannus forming process, the forming of MMPs (matrix metalloproteinases) and the new blood vessel can be inhibited, and the effect of preventing or treating the blood vessel and inflammatory diseases are realized; the polypeptides can be applied to the treatment of the blood vessel and inflammatory diseases, such as arthritis, inflammation, tumors, and eye diseases.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD
Continuous administration of cilengitide in cancer treatments
InactiveUS20120130146A1Prolonged progression-free survivalProlong median survivalAntibacterial agentsOrganic active ingredientsEfficacyIntegrin ligand
The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising the continuous administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agent or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy.
Owner:MERCK PATENT GMBH
Heterocyclic ligands for integrin imaging and therapy
ActiveUS8486370B2High affinityStrong specificityIn-vivo radioactive preparationsAntipyreticImmunologic disordersAutoimmune disease
The present invention provides α4β1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
Owner:RGT UNIV OF CALIFORNIA
Isolated organ perfusion combination therapy of cancer
InactiveUS20110165150A1Reduce morbidityReduce frequencyHeavy metal active ingredientsEnergy modified materialsLymphatic SpreadCombined Modality Therapy
The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and / or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.
Owner:MERCK PATENT GMBH
Specific therapy and medicament using integrin ligands for treating cancer
InactiveUS20100190957A1Increase volumeIncrease the number ofInorganic active ingredientsImmunoglobulinsLymphatic SpreadIntegrin antagonist
The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.
Owner:MERCK PATENT GMBH
Specific therapy using integrin ligands for treating cancer
InactiveCN101370522APrevention of disorderReduce incidenceOrganic active ingredientsPeptide/protein ingredientsLymphatic SpreadIntegrin antagonist
The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.
Owner:MERCK PATENT GMBH
Therapy and medicament using integrin ligands for treating cancer
InactiveUS20110230423A1Prolonged progression-free survivalProlong median survivalNervous disorderCyclic peptide ingredientsEfficacyIntegrin ligand
The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.
Owner:MERCK PATENT GMBH
Specific therapy and medicament using integrin ligands for treating cancer
InactiveCN101588812AReduce incidenceImprove the quality of lifePeptide/protein ingredientsInorganic active ingredientsIntegrin antagonistEfficacy
Owner:MERCK PATENT GMBH
Specific therapy and medicament using integrin ligands for treating cancer
InactiveUS20100069302A1Increase volumeIncrease the number ofPeptide/protein ingredientsInorganic active ingredientsLymphatic SpreadIntegrin antagonist
The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.
Owner:MERCK PATENT GMBH
Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
ActiveUS20160339098A1Antibody ingredientsCancer antigen ingredientsAdoptive cellular therapyAdjuvant
Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which may be used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to γδT-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti-CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).
Owner:TEXAS HEART INST +1
Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof
ActiveUS9340596B2Good curative effectEliminate side effectsPeptide/protein ingredientsPeptide preparation methodsSide effectApoptosis
Provided is a fusion protein comprising a tumor necrosis factor related apoptosis inducing ligand (TRAIL), integrin ligands of αVβ3 and αVβ5 and a linking peptide. Also provided are the expression method and simple separation and purification process for the production of the fusion protein which is soluble and has high content of the polymer, and use of the fusion protein for the manufacturing of a medicament for the treatment of tumor. The fusion protein has good tumor tissue targeting property, significantly enhanced anti-tumor effect, which can also reduce the dose of the needed protein for the target treatment effect, improve the bioavailability, reduce the treatment cost, decrease and overcome the potential toxic and side effects of the tumor necrosis factor-related apoptosis inducing ligand.
Owner:NANJING UNIV
Methods and compositions using integrin-based therapeutics
InactiveUS20180369330A1Avoid stickingOrganic active ingredientsConnective tissue peptidesDiseaseIntegrin ligand
The present invention is directed to modified integrin proteins and methods and compositions using integrin-based therapeutics. In one embodiment, the modified integrins demonstrate increased occurrence or duration of the E−H+ integrin protein conformation. In another embodiment, the compounds of the present invention stabilize E−H+ integrin protein conformation, increasing the occurrence or duration of the E−H+ integrin protein conformation. In another embodiment, the compounds of the present invention inhibit binding of a ligand of an integrin. In yet a further embodiment, the present compounds increase cis binding of the integrin or signaling based thereon. The present compounds decrease the occurrence or duration of trans binding of the integrin or signaling based thereon. The modified integrins and compounds described herein may be used in methods of treating immune modulated diseases or inflammatory diseases or conditions.
Owner:LA JOLLA INST FOR ALLERGY & IMMUNOLOGY
Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
ActiveUS10342866B2Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAdoptive cellular therapyAdjuvant
Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which may be used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to γδT-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti-CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).
Owner:TEXAS HEART INST +1
Integrin-targetable polypeptide mn and application thereof in preparing tumor targeting drugs
PendingCN111233975AImprove stabilityImproving immunogenicityMacromolecular non-active ingredientsHybrid peptidesPharmaceutical medicineTherapeutic effect
The present invention belongs to the field of pharmacy and relates to a highly stable multifunctional short peptide mn having high affinity with integrin and multi-functions of targeting tumor neovascularization, tumor mimic blood vessels and tumor cells, a polypeptide-modified complex, a drug delivery system and uses of the short peptide mn in preparation of drugs for tumor diagnosis and treatment. Experiment results show that mn-modified drugs are specifically taken up by integrin-expressing positive cells and tumor tissue, and have good tumor targeting and imaging functions; and a drug delivery system constructed by an mn-modified polymer carrier material effectively delivers entrapped drugs to target tissue and significantly improves the tumor diagnosis and treatment. Comparing the prepared drugs with widely used integrin ligand c (RGDyK), the mn has better stability in serum and stronger binding ability with the integrin, immunogenicity of a modified carrier system is significantly lower than a carrier system modified by the c (RGDyK), etc., mn-mediated in-vivo active targeting drug delivery effects are more effective and the mn has good application prospects in the tumor diagnosis and targeted therapy.
Owner:FUDAN UNIV
Isolated organ perfusion combination therapy of cancer
InactiveCN101370512AReduce incidenceReduce the number of hospitalizationsEnergy modified materialsDigestive systemLymphatic SpreadCombined Modality Therapy
The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and / or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.
Owner:MERCK PATENT GMBH
Application of blood vessel inhibitory polypeptide with integrin affinity and binding ability and matrix metalloproteinase inhibitory ability
ActiveCN104840941BII works wellInhibition formationSenses disorderPeptide/protein ingredientsDiseaseArginine
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD
Research method for restraining porcine epidemic diarrhea virus infection based on integrin ligand recognition peptides
ActiveCN111575409AAvoid stickingInhibition of internalizationMicrobiological testing/measurementBiological material analysisIntegrin ligandCultured cell
The invention discloses a research method for restraining porcine epidemic diarrhea virus infection based on integrin ligand recognition peptides. The method comprises the following steps of S1, diluting a Vero E6 cell suspension, and placing the diluted Vero E6 cell suspension in a cell culture incubator for culturing; S2, when cell density achieves 90%, removing a culture medium, and performingmoistening; S3, adding the cells to a basic culture medium containing the integrin ligand recognition peptides, and performing hatching; S4, after the liquid is removed, adding virus maintaining liquid; S5, performing inoculating with porcine epidemic diarrhea viruses; S6, after the Vero E6 cells inoculated with the viruses are placed in the cell culture incubator for 2h, sucking liquid; S7, adding the virus maintaining liquid, and placing mixed liquid in the cell culture incubator for culturing; S8, storing cells; S9, collecting samples, and performing real-time fluorescent quantitation PCR;S10, collecting samples, and performing western blotting; and S11, counting research results. The research method can verify whether the integrin ligand recognition peptides est, com and er have the effect of resisting PEDV infection, and reference is provided for prevention and control of PED and development of antiviral drugs.
Owner:HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY
Integrin blocker polypeptide and its application in the preparation of drugs for the treatment of neovascular eye diseases
ActiveCN104327169BSuppress generationInhibition formationSenses disorderPeptide/protein ingredientsDiseaseIntegrin ligand
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD
Drug carried tumor-targeted cationic polymer for injections and modified by integrin ligand
InactiveCN101284133BEasy to prepareSuitable for mass productionPowder deliveryMacromolecular non-active ingredientsTumor targetCationic polymerization
The invention belongs to the technology field of a tumor targeting and slow release drug delivery system, and relates to a drug-carrying tumor targeting cationic polymer. The surface of the cationic polymer is modified by linear chain or cyclic polypeptide containing RGD sequence to obtain a series of cationic polymers. The obtained cationic polymers can be used for the preparation of anticancer drug-carrying nano-particle drug-delivery system. The nano-particle slow release in combination with tumor targeting effect of RGD increases accumulation of the anticancer drug in tumor part and inhibits tumor growth by breaking tumor new vessels to improve drug curative effect.
Owner:SHANGHAI INST OF ONCOLOGY
Long circulation liposome with modified integrin and carried anticancer medicine for injection
InactiveCN100431609CImprove therapeutic indexIncrease intakeMacromolecular non-active ingredientsAntineoplastic agentsGlycineAnticarcinogen
The present invention relates to integrin ligand modified long circulation liposome carrying anticarcinogen for injection, and is especially one kind of injected anticarcinogen carrying targeting liposome administration system. The efficient administration system is obtained through modifying the surface of liposome simultaneously with both polyethylene glycol and integrin containing arginine-glycine-asparagic acid sequence or RGD analogue.
Owner:PEKING UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com